Priavoid’s Alzheimer’s pill fails to prove efficacy in phase 2 trial

Brain scan, neuroscience
Priavoid noted that the per-protocol population showed a statistically significant 35.9% slowing of cognitive decline at Week 72. (Martin Philip/iStock/Getty Images Plus)

Priavoid’s pill for Alzheimer's disease has failed to prove its effectiveness in a phase 2 dementia study, although the German biotech pointed to encouraging signs in the longer-term data.

The Düsseldorf-based company evaluated two doses of the orally available all-D-peptide candidate, dubbed PRI-002, in the mid-stage PRImus-AD trial of 304 patients aged between 55 and 80 years with mild cognitive impairment or mild dementia due to Alzheimer's.

The study failed to show a change from baseline at Week 48 as measured by a clinical dementia rating scale—missing the trial’s primary endpoint.

The company pointed to “promising signals across key measures of cognition and daily functioning, with numerical difference favoring PRI-002.” Specifically, Priavoid noted that the per-protocol population—patients who followed the study protocol without major deviations—showed a statistically significant 35.9% slowing of cognitive decline at Week 72 compared to placebo when measured on a separate Alzheimer’s assessment scale.

Priavoid described this as an “encouraging signal for further investigation.” 

When it came to an early look at biomarkers, the company noted that p-tau181 levels were “consistent with PRI-002's proposed biological activity,” with differentiation starting at 24 weeks.

“Further evaluation of Alzheimer's disease-related biomarkers and brain volumetric measurements will help clarify the relationship between PRI-002's proposed mechanism of action and the observed clinical findings,” the biotech added.

Meanwhile, the study hit its other primary endpoint of safety, with the most common adverse events being headache, nausea and dizziness, according to Priavoid.

ARIA-H—small brain bleeds or iron deposits in the brain—was seen in 8% of patients on the 300 mg dose of PRI-002, 11.7% of the 600 mg cohort and 5% of the placebo group. When it came to ARIA-E—a temporary buildup of fluid in the brain—the rates were 2%, 0% and 1%.

“We are encouraged by the clinical signals observed in PRImus-AD, particularly the findings favoring PRI-002 in measures of cognition and daily functioning,” Priavoid Chief Medical Officer Oliver Peters said in a Nov. 18 release.

“PRI-002 has demonstrated a favorable safety and tolerability profile, combined with a convenient oral treatment regimen,” Peters added. “For people living with Alzheimer's disease, a treatment that could slow cognitive and functional decline while fitting into their daily lives would contribute to quality of life. We look forward to further exploring these findings and defining the next steps in PRI-002’s clinical development.”

PRI-002’s origins lie at the Heinrich Heine University in Düsseldorf as well as the Jülich Research Centre. Unlike the approved anti-amyloid monoclonal antibodies for Alzheimer’s—which aim to clear plaques—the idea behind PRI-002 is to target Aβ oligomers, which are believed to be a key driver of Alzheimer’s. 

By binding to neurotoxic Aβ oligomers, PRI-002 aims to cause these oligomers to disassemble into non-toxic monomers, thereby addressing Alzheimer’s neurotoxicity at its source while avoiding serious side effects like ARIA.